Cognitive Impairment clinical trials

Explore recruiting cognitive impairment clinical trials.

Recruiting cognitive impairment studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cognitive Impairment trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Longitudinal multicenter head-to-head harmonization of tau PET tracers (HEAD Study)

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A prospective, open-label, single-arm, multicenter study evaluating the efficacy of Xanomeline/Trospium (XT) on cognitive impairment after 24 and 52 weeks of treatment in adult participants with schizophrenia.

Denmark, Belgium, Italy, Netherlands, Hungary, Czechia +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase 1, randomized, double-blind, placebo-controlled study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of VNA-318 in healthy male subjects

France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A phase 1, randomized, double-blind, placebo-controlled study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of VNA-318 in healthy male subjects

France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A double-blinded, randomized, placebo-controlled, multi-center trial of Efgartigimod in autoimmune dementia (EfgaDem)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

LiBRA – Lithium treatment to prevent cognitive impairment after brain radiotherapy.

Sweden, Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

Cognitive Impairment trials by city

Cognitive Impairment in Toronto Cognitive Impairment in Vancouver Cognitive Impairment in Montreal Cognitive Impairment in Calgary Cognitive Impairment in Edmonton Cognitive Impairment in Ottawa Cognitive Impairment in Winnipeg Cognitive Impairment in Quebec City Cognitive Impairment in Hamilton Cognitive Impairment in Kitchener Cognitive Impairment in London Cognitive Impairment in Halifax Cognitive Impairment in New York Cognitive Impairment in Los Angeles Cognitive Impairment in Chicago Cognitive Impairment in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease